Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

Clinical trial NCT07724457 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07724457
Sponsor: National Cancer Institute (NCI)
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Recurrent Burkitt Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements Refractory Burkitt Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Start date: 2026-10-30
Primary completion: 2033-11-01
Enrollment: 271

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.